Researcher
Kevin Punie
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From28 Feb 2017 → Today
Projects
1 - 2 of 2
- Novel biomarkers in the risk stratification, surveillance and treatment of young breast cancer patients and germline carriers of pathogenic variants in TP53.From1 Sep 2020 → 13 Feb 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Relapse in breast and gynaecological cancers.From1 Feb 2019 → 1 Oct 2021Funding: Private funding of national origin - undefined
Publications
21 - 30 of 75
- Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer(2021)
Authors: Kevin Punie
Pages: 1148 - 1156 - Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.(2021)
Authors: Lisa Kinget, Oliver Bechter, Kevin Punie, Hilde Brems, Paul Clement, Eduard Roussel, Yannick Van Herck, Maarten Albersen, Marcella Baldewijns, Patrick Schöffski, et al.
Pages: 3227 - 3239 - Solving current dilemmas in the adjuvant endocrine treatment of pre- and perimenopausal women with an estrogen receptor positive breast cancer(2021)
Authors: Sileny Han, Kevin Punie, Hans Wildiers, Patrick Neven
Pages: 621 - 633 - Theconcerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II(2021)
Authors: Kevin Punie
- Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3(2021)
Authors: Lore De Cock, Jannes Heylen, Kevin Punie, Ann Smeets, Caroline Weltens, Patrick Neven, Annouschka Laenen, Hans Wildiers
Pages: 1 - 9 - Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study(2021)
Authors: Kevin Punie, Hans Wildiers
Pages: 1 - 12 - Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.(2021)
Authors: Kevin Punie
Pages: 945 - 962 - Sacituzumab govitecan and trastuzumab deruxtecan: two new antibodyedrug conjugates in the breast cancer treatment landscape(2021)
Authors: Hans Wildiers, Patrick Neven, Kevin Punie
Pages: 1 - 13 - Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2-early breast cancer(2021)
Authors: Laurence Slembrouck, Isabelle Vanden Bempt, Hans Wildiers, Ann Smeets, Anne-Sophie Van Rompuy, Chantal Van Ongeval, Caroline Weltens, Kevin Punie, Els Van Nieuwenhuysen, Sileny Han, et al.
Pages: 1297 - 1309 - Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis(2021)
Authors: Kevin Punie